Pharma wars: Shire share price leaps as AbbVie hikes offer to £51.15 July 8, 2014 US-based pharmaceuticals company AbbVie has hiked its offer for Shire to £51.15 per share in the form of cash and shares. Following AbbVie's 25 June announcement it has said that it has "met with, or spoken to, a large number of Shire shareholders, who collectively represent a majority of Shire's outstanding shares". "The majority of [...]
AbbVie’s boss Rick Gonzalez jets in to chat up Shire investors about £27bn deal June 30, 2014 The chief executive of an American drug firm chasing UK rival Shire will lay the ground for a fourth bid to buy the group this week by touring City shareholders. AbbVie chief executive and chairman Rick Gonzalez will troop around Shire’s shareholders, which include fund managers like BlackRock and Legal & General Investment Management, to [...]
Patent victory fortifies Shire against AbbVie June 25, 2014 Pharmaceutical group Shire rejected a bid by US firm AbbVie yesterday, as it cheered a court ruling in its favour over a drug patent. Shire has already rejected the $46bn (£27.1bn) offer and said that the attempt undervalued it, reaffirming its stance today. The bid for Shire was AbbVie’s third, and it now might launch a [...]
Shire share price leaps by more than 500p on AbbVie approach June 20, 2014 London-listed pharma company Shire has turned its nose up at an approach from AbbVie. A statement from AbbVie released this morning confirms that bids were knocked back three times. AbbVie, a Chicago based company, first offered an initial cash and share proposal in early May, valuing Shire at around £39.50 per share. By their third [...]